You are here

TGA Internet site archive

The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.

ARGCM Part C, V7.2 February 2018 (archived)

Australian Regulatory Guidelines for Complementary Medicines

15 February 2018

The following documents are provided for historical purposes only. Please see Australian regulatory guidelines for complementary medicines for up-to-date guidance.

ARGCM Part C: New complementary medicine substance evaluation

This guidance is for applicants proposing new substances for use as an ingredient in listed medicines. You can submit an application for evaluation for suitability for use in listed medicines for:

  • a new complementary medicine substance not currently a permitted ingredient; or
  • a proposed new role or a change to a regulatory requirement of use for a permitted ingredient, for example: a proposal for an ingredient permitted for use as an excipient to be used as an active ingredient; or change to the permitted level of use; or change the permitted route of administration.

A request for evaluation of a new complementary medicine substance is considered under Regulation 16GA of the Therapeutic Goods Regulations 1990 (the Regulations). There is an associated fee.

The primary reason for the evaluation of a substance is to determine whether it is of appropriate quality and safety to be permitted for use as an ingredient in listed complementary medicines.

Once permitted for use in listed medicines, an ingredient may be used in a listed medicine by any sponsor.